News
Public · Published
Piramal Pharma surges 18% to 18-month high as Q2 results beat estimates; brokerage upgrades to Add, check target price
Piramal Pharma shares jumped over 18 percent to an 18-month high of Rs 235.22 after it reported a September-quarter net profit of Rs 5 crore, versus a Rs 99.22 crore loss a year earlier. Revenue rose over 28 percent to Rs 2,617 crore.
Published:
Updated:
What happened
Piramal Pharma shares jumped over 18 percent to an 18-month high of Rs 235.22 after it reported a September-quarter net profit of Rs 5 crore, versus a Rs 99.22 crore loss a year earlier. Revenue rose over 28 percent to Rs 2,617 crore.
Confirmed
Global impact / market context
A surprise profit ends a long run of losses, showing sales growth outpaced rising expenses and eased pressure on the company's cash and borrowing needs. Investors may reprice the stock as earnings quality improves rather than staying a turnaround bet.
Analyst inference
The rally put Piramal Pharma among the top Nifty 500 performers, signaling that investors reward clear earnings surprises. A brokerage upgrade to Add with a target price reinforced the shift, though the stock's sharp move shows expectations were low before results.
Analyst inference
What to watch
- Piramal Pharma's revenue rose over 28 percent year-on-year and over 15 percent sequentially to Rs 2,617 crore, while total expenses grew to Rs 2,589.10 crore from Rs 2,170.29 crore a year earlier. Confirmed
- Watch whether the company can repeat this profit in coming quarters, since one strong quarter does not confirm a lasting turnaround; a return to losses would test the brokerage upgrade to Add. Proposed
- Track whether sales keep growing faster than expenses, because that gap drove the surprise profit; if cost growth catches up, profit per sale, which means margin, could shrink and pressure the stock. Analyst inference
Evidence
- Original source link unavailable